The Pharma Data
NOVEMBER 19, 2020
The Company is also aiming to leverage the highly conserved structure of the SARS-CoV-2 M pro protease as a basis for the design of novel oral small molecules against predicted future variants of SARS-CoV-2 and other related human viruses. 2014), 281, 4085-4096. References. Hilgenfeld, Febs J. Pillaiyar, et al, J.
NIH Director's Blog: Drug Discovery
APRIL 11, 2017
Researchers soon began screening a chemical library and its more than 380,000 traditional drug candidates to find the right small-molecule inhibitor, the preferred compound in drug discovery. Missing was the usual pocket-shaped active site, where a traditional small molecule can readily bind and block function.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Molecular Design
DECEMBER 31, 2024
My pulse will be quickenin' With each drop of strychnine We feed to a pigeon It just takes a smidgin To poison a pigeon in the park Tom Lehrer, Poisoning Pigeons in the Park | video ** Ill be reviewing the H2024 study (Occurrence of Natural Selection in Successful Small Molecule Drug Discovery) in this post. fold and it's worth ).
PLOS: DNA Science
SEPTEMBER 5, 2024
Gleevec is a small molecule that interferes with entry of an enzyme – a tyrosine kinase – that enables growth signals to enter specific cells and trigger division. FDA-approved in 2014, Keytruda was the first “programmed death receptor-1 (PD-1) inhibitor.”
The Pharma Data
OCTOBER 25, 2020
Vatiquinone, developed from PTC’s Bio-e platform, is an investigational oral small molecule that inhibits 15-Lipoxygenase, a key enzyme that regulates oxidative stress and inflammation response pathways underpinning many neurological disease pathologies, including epilepsy. 2014; View original content: [link].
The Pharma Data
NOVEMBER 1, 2020
He joins Mission from VHsquared, where he held the position of CMO since 2014. Dr Nurbhai has more than 25 years of experience and a strong track record in the strategic and operational leadership of all phases of clinical research and development at companies across Europe and the US.
The Pharma Data
OCTOBER 21, 2020
Importantly, the manufacturing process for our small molecule direct-acting antiviral allows us to produce AT-527 quickly and at scale.”. Founded by its Chairman and Chief Executive Officer, Jean-Pierre Sommadossi, PhD, Atea began operations in 2014 and is headquartered in Boston, MA. ” About AT-527.
Expert insights. Personalized for you.
40 
Let's personalize your content